ArticleLancet (London, England)2018
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.
Article in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 1,790 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Seasonal Influenza Vaccine Uptake Among Health Care Workers Following Awareness and Availability of Influenza Vaccine Supply in Tertiary Care Hospitals, Bangladesh
INFLUENCEF STUDY: Epidemiology, Risk Factors and Clinical Phenotype of Headache Associated With Influenza Infection
Who cites it
1,790 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Maternal influenza vaccination during the first trimester of pregnancy and risk for birth defects: an updated systematic review and meta-analysis.BMC pregnancy and childbirth · 2026Pooled it
- Influenza vaccination and cardiovascular and respiratory outcomes in high-risk populations: an umbrella review of systematic reviews and meta-analyzes.Frontiers in immunology · 2026Pooled it
- Intranasal natural products for influenza treatment: a systematic review and meta-analysis of preclinical studies.Frontiers in immunology · 2026Pooled it
- Comparison of safety and immunogenicity between high-dose and low-dose quadrivalent influenza vaccines in children aged 6-35 months in China: A randomized, double-blind clinical study.Human vaccines & immunotherapeutics · 2026Trial
- Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.Human vaccines & immunotherapeutics · 2026Trial
- Impact of Influenza Vaccination during Pregnancy on Maternal Influenza Disease Severity in Rural Nepal.The American journal of tropical medicine and hygiene · 2026Trial
- Development of a pandemic H5N1 influenza vaccine using MDCK suspension cells: A scalable and efficient production platform.Human vaccines & immunotherapeutics · 2026Article
- Respiratory pandemic risk in the Anthropocene: A One Health framework and GISRS+ agenda.One health (Amsterdam, Netherlands) · 2026Review
- Emergence of the novel PA-D27G mutation conferring reduced baloxavir susceptibility in influenza A viruses circulating in China, 2018-2025.Emerging microbes & infections · 2026Article
- Influenza vaccine Hesitancy in older adults in China: A latent profile analysis.Human vaccines & immunotherapeutics · 2026Article
- AXL mediates influenza A virus entry and drives virus-induced inflammation.Emerging microbes & infections · 2026Article
- Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.Emerging microbes & infections · 2026Article
- Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».Reviews in medical virology · 2026Review
- Polyclonal breast milk-derived secretory IgA confers broad antiviral protection against multiple respiratory viruses.Science advances · 2026Article
- Temporal and transcriptional programming of effector memory B cells shapes vaccine platform-dependent humoral immunity.iScience · 2026Article
- A Phase 2 Trial Evaluating the Immunogenicity and Safety of an mRNA-Based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase.Infectious diseases and therapy · 2026Article
- A Phase 1/2 Trial Evaluating the Safety and Immunogenicity of an mRNA-based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase.Infectious diseases and therapy · 2026Article
- Influenza vaccine protection and contact patterns among outpatients with influenza-like illness during the 2024-2025 season in China: a test-negative case-control study.Journal of global health · 2026Article
- Budget impact analysis of implementing point-of-care molecular testing for influenza A&B and RSV in Saudi older adult patients across hospital and home-care settings.Health economics review · 2026Article
- Using interpretable machine learning models to predict the occurrence of severe influenza in hospitalized children: a retrospective cohort study.BMC medical informatics and decision making · 2026Article
1,730 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
26 authors.
Funding
Abstract
backgroundEstimates of influenza-associated mortality are important for national and international decision making on public health priorities. Previous estimates of 250 000-500 000 annual influenza deaths are outdated. We updated the estimated number of global annual influenza-associated respiratory deaths using country-specific influenza-associated excess respiratory mortality estimates from 1999-2015.
methodsWe estimated country-specific influenza-associated respiratory excess mortality rates (EMR) for 33 countries using time series log-linear regression models with vital death records and influenza surveillance data. To extrapolate estimates to countries without data, we divided countries into three analytic divisions for three age groups (<65 years, 65-74 years, and ≥75 years) using WHO Global Health Estimate (GHE) respiratory infection mortality rates. We calculated mortality rate ratios (MRR) to account for differences in risk of influenza death across countries by comparing GHE respiratory infection mortality rates from countries without EMR estimates with those with estimates. To calculate death estimates for individual countries within each age-specific analytic division, we multiplied randomly selected mean annual EMRs by the country's MRR and population. Global 95% credible interval (CrI) estimates were obtained from the posterior distribution of the sum of country-specific estimates to represent the range of possible influenza-associated deaths in a season or year. We calculated influenza-associated deaths for children younger than 5 years for 92 countries with high rates of mortality due to respiratory infection using the same methods.
findingsEMR-contributing countries represented 57% of the global population. The estimated mean annual influenza-associated respiratory EMR ranged from 0·1 to 6·4 per 100 000 individuals for people younger than 65 years, 2·9 to 44·0 per 100 000 individuals for people aged between 65 and 74 years, and 17·9 to 223·5 per 100 000 for people older than 75 years. We estimated that 291 243-645 832 seasonal influenza-associated respiratory deaths (4·0-8·8 per 100 000 individuals) occur annually. The highest mortality rates were estimated in sub-Saharan Africa (2·8-16·5 per 100 000 individuals), southeast Asia (3·5-9·2 per 100 000 individuals), and among people aged 75 years or older (51·3-99·4 per 100 000 individuals). For 92 countries, we estimated that among children younger than 5 years, 9243-105 690 influenza-associated respiratory deaths occur annually.
interpretationThese global influenza-associated respiratory mortality estimates are higher than previously reported, suggesting that previous estimates might have underestimated disease burden. The contribution of non-respiratory causes of death to global influenza-associated mortality should be investigated.
fundingNone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.